Items where authors include "Zanatta, E."
Article
Di Donato, S. orcid.org/0000-0003-1256-0761, Pauling, J.D., Ramjug, S. et al. (149 more authors) (2025) Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort. Rheumatology. keaf290. ISSN 1462-0324
Roth, E., Bruni, C., Petelytska, L. et al. (244 more authors) (2025) Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatology. keaf016. ISSN 1462-0324
Wyss, A., Jordan, S., Graf, N. et al. (18 more authors) (2024) Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis. Arthritis Research & Therapy, 26. 187. ISSN 1478-6354
Colalillo, A., Hachulla, E., Pellicano, C. et al. (35 more authors) (2024) Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis. Chest Journal, 166 (4). pp. 837-844. ISSN 0012-3692
Velauthapillai, A., Bootsma, M.F.R., Bruni, C. et al. (118 more authors) (2024) Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis. Rheumatology. keae375. ISSN 1462-0324
Deibel, E. orcid.org/0000-0003-4652-9826, Carreira, P.E., Vonk, M. orcid.org/0000-0002-2266-9907 et al. (61 more authors) (2024) Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? Arthritis Care & Research, 76 (1). pp. 88-97. ISSN 2151-464X
Hughes, M., Huang, S., Alegre-Sancho, J.J. et al. (98 more authors) (2023) Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 62 (SI). SI54-SI63. ISSN 1462-0324
Garaiman, A., Steigmiller, K., Gebhard, C. et al. (171 more authors) (2023) Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology, 62 (SI). SI91-SI100. ISSN 1462-0324
Kuster, S., Jordan, S., Elhai, M. et al. (104 more authors) (2022) Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open, 8 (2). e002477. ISSN 2056-5933
Campochiaro, C. orcid.org/0000-0001-6806-3794, Hoffmann-Vold, A.-M. orcid.org/0000-0001-6467-7422, Avouac, J. et al. (90 more authors) (2022) Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis. Rheumatology, 62 (7). pp. 2483-2491. ISSN 1462-0324
Elhai, M., Sritharan, N., Boubaya, M. et al. (167 more authors) (2022) Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. The Lancet Rheumatology, 4 (11). e785-e794. ISSN 2665-9913
Lazzaroni, M-G., Marasco, E., Campochiaro, C. et al. (30 more authors) (2021) The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology, 60 (11). pp. 5028-5041. ISSN 1462-0324
Proceedings Paper
Benfaremo, D., Campochiaro, C., Kumánovics, G. et al. (16 more authors) (2025) OP0085 Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease (SSc-ILD): results from an EUSTAR cohort study. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , p. 75.
D'Alessandro, R., Rodolfi, S., Calot, A. et al. (20 more authors) (2025) ABS0554 FEATURES OF ANTI-FIBRILLARIN POSITIVE SYSTEMIC SCLEROSIS PATIENTS AND ETHNIC DIFFERENCES: A EUROPEAN MULTICENTRIC COHORT. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , pp. 2294-2295.
Benfaremo, D., Campochiaro, C., Kumanovics, G. et al. (16 more authors) (2025) OP0085 Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease (SSc-ILD): results from an EUSTAR cohort study. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. , p. 75.
Bruni, C., Tofani, L., Fretheim, H. et al. (55 more authors) (2023) OP0238 Immunosuppression With Targeted Dmards Reduces Morbidity And Mortality In Pre-Capillary Pulmonary Hypertension Associated With Systemic Sclerosis: A Eustar Analysis. In: Annals of the Rheumatic Diseases (ARD). EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 157-159.